Hoechst Aktiengesellschaft

Glycorex Ab

Aventis Pharma Deutschland, Gmbh

UniversitÄtsmedizin Der Johannes Gutenberg-Universitat Mainz

Orpegen Medizinische-molekular Biologische Forschungsgesellschaft Mbh

Johannes Gutenberg-Universität Mainz

Horst Kunz

Wolfgang Schmidt

Gerhard Kretzschmar

Ulrich Sprengard

Peter Braun

Stephan Henke

Dirk Seiffge

Eckart Bartnik

Winfried Kosch

Edgar Schmitt

Robert Klein

Till Opatz

Joachim Marz

Gunther Braum

Nikola Gaidzik

Natascha Stergiou

Tobias Wunberg

Christopher Kallus

Gnther Braum

The present invention relates to a compound comprising a first polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of GFTFSDYW (SEQ ID NO: 1), IRLKSNNYAA (SEQ ID NO: 2) and TFGNSFAY (SEQ ID NO: 3), a second polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of TGAVTTNNY (SEQ ID NO: 4), GTN (SEQ ID NO: 5) and ALWYSNHWV (SEQ ID NO: 6), or a variant of any one of said amino acid sequences of SEQ ID NO: 1 to SEQ ID NO: 6 having a different amino acid at one position, wherein said compound or variant is capable of binding to tumour-associated Mucin-1 (TA-MUC1).

Peptide-based compounds for use in the prevention, treatment and/or detection of cancer

Substituted tetrahydropyrane derivatives, method for producing same, their use as medicine or diagnostic agent, as well as medicine containing same

The invention relates to novel mimetics of the tetrasaccharides sialyl-Lewis-X and sialyl-Lewis-A having an improved action as inhibitors of cell adhesion, to a process for the preparation of these compounds and to their use as pharmacological active compounds and diagnostic agents.

Glycomimetics as selectin antagonists and pharmaceuticals having antiinflammatory activity

The invention relates to novel mimetics of the tetrasaccharides sialyl- Lewis-X (SLeX) and sialyl- Lewis-A (SLeA) having an improved action as inhibitors of cell adhesion, specifically a compound of the formula I

Glycomimetics as selectin antagonists and pharmaceuticals having antiinflammatory activity prepared therefrom

The invention relates to novel conjugates of tetrasaccharides, preferably of sialyl-Lewis X (SLeX) and sialyl-Lewis A (SLeA), having improved activity as inhibitors of cell adhesion, a process for the preparation of these compounds, and their use as pharmacological active compounds and as diagnostics and pharmaceuticals which contain these conjugates.

Carbohydrate conjugates as inhibitors of cell adhesion

Carboxylate protective groups, a process for their preparation, their coupling to a funcitonal group, and their use Carboxylates of polar, hydrophilic alcohols of the formula ##STR1## in which R is an unbranched or branched organic radical which contains, as polar members between aliphatic or araliphatic hydrocarbon bridges, ether oxygens, amine nitrogen groups or a mixture of ether and amine groups which can be incorporated into a cyclic structure, where the total length does not exceed 20 members and where, in the case of polyethylene glycol [(CH.sub.2 --CH.sub.2 --O).sub.n ], n indicates the number of the members and is defined as any integer, and

Carboxylate protective groups, a process for their preparation, their

Carboxylates of polar, hydrophilic alcohols of the formula ##STR1## in which R is an unbranched or branched organic radical which contains, as polar members between aliphatic or araliphatic hydrocarbon bridges, ether oxygens, amine nitrogen groups or a mixture of ether and amine groups which can be incorporated into a cyclic structure, where the total length does not exceed 20 members and where, in the case of polyethylene glycol [(CH.sub.2 --CH.sub.2 --O).sub.n ], n indicates the number of the members and is defined as any integer, and R' is an aliphatic or araliphatic radical which has at least one functional group, are suitable as protective groups since they can be introduced selectively into functional groups of organic compounds and eliminated specifically by lipases.

The invention provides a method for the production of a solid phase system of the formula F--(--R.sup.3 --Y--CO--CR.sup.2 .dbd.CR.sup.1 --CH.sub.2 --X).sub.m using new allyl esters of the formula:

Process for preparation of a solid phase system

Growing community of inventors

Mainz, Germany

Horst Kunz